Printed from Voxsanity (voxsanity.com.au) — NCT06188455 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Ovarian Cancer
Phase 3 Ovarian Cancer Trial, Not Yet Recruiting
NCT06188455
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- Women aged 18 to 75 years old.
- People who have been diagnosed through tissue or cell testing with epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
- People who previously received platinum-based chemotherapy as their first treatment, and either: their cancer came back or got worse within 6 months of finishing that treatment (called platinum-resistant), or their cancer came back or got worse 6 months or more after finishing that treatment (called platinum-sensitive) — and in either case, their cancer responded to or stabilised with at least 4 more cycles of chemotherapy after that recurrence.
- People who have at least one tumour that can be measured on a scan, meeting specific size requirements set out in standard medical guidelines (confirm with trial site).
- People with a good general activity level, rated 0 or 1 on a standard medical scale that measures how much a condition affects daily life (confirm with trial site).
- People whose blood test results meet specific levels for red blood cells, white blood cells, platelets, and other blood counts, without having had a blood transfusion in the 14 days before testing (confirm with trial site for exact values).
- People whose liver and kidney function blood test results fall within acceptable ranges as set by the trial (confirm with trial site for exact values).
- People whose blood clotting test results are within acceptable ranges, or — if already on blood thinning medication — whose clotting results are within the expected range for that medication.
- People who do not have serious heart, lung, liver, or kidney conditions.
- Women who could become pregnant must have a negative pregnancy blood test within 7 days before joining, and must agree to use appropriate contraception during the trial and for 8 weeks after the last dose of the study drug.
- People whose doctors expect them to live at least 6 months overall, and at least 3 months after starting treatment.
- People who are willing and able to sign a consent form and follow the trial's visit schedule and procedures.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who are currently taking part in another clinical trial using a different experimental drug at the same time.
- People who are receiving other cancer treatments at the same time as this study, including chemotherapy, radiation, targeted therapy, immunotherapy, or other experimental therapies.
- People known to be allergic to fluzoparil or to ingredients in drugs with a similar chemical structure.
- People known to be allergic to apatinib or to ingredients in drugs with a similar chemical structure.
- People who cannot swallow tablets or capsules, or who have digestive system problems that could affect how the study drug is absorbed, such as uncontrolled nausea and vomiting, bowel blockage, or malabsorption.
- People who have cancer that has spread to the brain and is causing symptoms or is not controlled, or who have signs of pressure on the spinal cord.
- People who have had another type of cancer in the past 3 years, with the exception of certain skin cancers, a specific type of non-invasive breast condition, or non-invasive cervical cancer (confirm with trial site for exact definitions).
- People who have been diagnosed with myelodysplastic syndrome (MDS) or acute myeloid leukaemia (AML) at any point.
- People who have had a bowel blockage or a hole in the digestive tract within the past 3 months.
- People with certain heart conditions that are not well controlled, including significant heart failure, unstable chest pain, a heart attack within the past year, certain serious irregular heart rhythms, or abnormal heart electrical readings above a specific level (confirm with trial site for exact values).
- People who have had a significant bleeding event within 4 weeks before starting the trial (confirm with trial site for exact definition of severity).
- People with high blood pressure that is not well controlled by medication, specifically a reading of 140/90 mmHg or higher.
- People who have or have had certain lung conditions, including pulmonary fibrosis, interstitial lung disease, or drug-related lung problems, or who show signs of active lung inflammation on a scan during screening.
- People who have abnormal blood clotting results and a tendency to bleed, or who are receiving clot-dissolving or blood-thinning therapies — noting that low-dose preventive blood thinning may be permitted during the trial (confirm with trial site).
- People who have been diagnosed with a deep vein blood clot, except for a specific minor type (confirm with trial site).
- People with a personal or family history of bleeding or clotting disorders, or who have had significant bleeding symptoms such as gastrointestinal bleeding in the 3 months before joining.
- People with a weakened immune system due to a congenital or acquired condition such as HIV, or who have active hepatitis B or hepatitis C meeting specific test thresholds (confirm with trial site for exact values).
- People who received a platelet or red blood cell transfusion within 4 weeks before starting the study drug.
- People who are pregnant, breastfeeding, or planning to become pregnant during the study treatment period.
- People whom the research team considers unsuitable for the trial for other reasons that could affect their safety or the study results.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Not Yet Recruiting
Phase
Phase 3
Sponsor
The First Affiliated Hospital of Xiamen University
Registry
ClinicalTrials.gov
Start date
1 December 2024
Est. completion
1 December 2025
This date has passed while the registry still lists the trial as open to participants. Sponsors often update a trial's status without revising its projected end date, so it may well still be recruiting — but the record is out of date in at least one respect. Check with the study contact before relying on either.
Primary endpoints
PFS
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.